Products with Anti-Atherosclerotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5171 | Geniposidic acid |
| Geniposidic acid is an effective anticancer and radioprotection agent, used to treat inflammation, jaundice and hepatic disorders. It has anti-atherosclerotic effects, can protect vascular endothelium and reverse plaque formation in an atherosclerotic model. Geniposidic acid has effects on the expression of MRP2 and BSEP in BRL-3A cells after FXR gene silencing mediated by si RNA. | |
| BCN5266 | Alpinumisoflavone |
| 1. Alpinumisoflavone has atheroprotective effects, may result from their ability to upregulate mechanisms promoting HDL-cholesterol and bile acid formation. 2. Alpinumisoflavone is endowed with estrogenic properties accounting, at least in part, for E. lysistemon effects. 3. Alpinumisoflavone induces cell death, may be via repressing both the ERK/MAPK and NF-κB pathways. 4. Alpinumisoflavone, abyssione-V 4'-O-methyl ether, 6,8-diprenylgenistein, and burttinone are active against both Gram-negative and Gram-positive bacteria, the minimum inhibitory concentration values obtained (MIC) ranged from 3.9 ug/mL to 125 ug/mL. | |
| BCN5304 | Cryptotanshinone |
| Cryptotanshinone is a potent STAT3 inhibitor with IC50 of 4.6 μM, and inhibits STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells. It is also an AR inhibitor to suppress androgen/AR-mediated cell growth and PSA expression by blocking AR dimerization and the AR-coregulator complex formation. Cryptotanshinone has anti-atherosclerosis, neuroprotective, anti-cancer,and anti-neointimal formation activities. Cryptotanshinone reverses DEX-induced androgen excess and ovarian IR in mice through activation of insulin signaling and the regulation of glucose transporters and hormone-synthesizing enzymes, it has an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells treated with TNF-alpha in a dose-dependent manner. | |
| BCN5344 | Buddlejasaponin IV |
| 1. Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation, are responsible for the anti-inflammatory effects of buddlejasaponin IV. 2. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat. 3. Buddlejasaponin IV exerts antiinflammatory and cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes. 4. Buddlejasaponin IV may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. | |
| BCN5375 | Folic acid |
| Folic acid supplementation improves arterial endothelial function in adults with relative hyperhomocystinemia, with potentially beneficial effects on the atherosclerotic process. Both local perfusion of 5-MTHF and supplementation with folic acid increase vasodilatation in ageing individuals through NO-dependent mechanisms. The combined use of enalapril and Folic acid significantly reduced the risk of first stroke, folic acid deficiency and homocysteine impaired DNA repair in hippocampal neurons and sensitized them to amyloid toxicity. | |
